Abstract Alzheimer's disease (AD) is thought to progress in a fairly stereotyped manner, with episodic memory loss being the first and most salient domain of impairment, reflecting the early disease in structures supporting this function. However, there is considerable heterogeneity in the relative involvement of different cognitive domains, and at the extreme are three syndromes associated with AD: (1) logopenic progressive aphasia, (2) posterior cortical atrophy, and (3) frontal variant of AD. As each of these syndromes is variably associated with non-AD dementia and clinically overlaps with other presentations more commonly associated with different causes of neurodegeneration (e.g., progressive nonfluent aphasia), the use of amyloid imaging for detection of the molecular pathologic features of AD is of significant clinical value. This article reviews several amyloid imaging studies of these populations which support autopsy case series and reveal a dissociation between the spatial distribution of amyloid plaques and clinical phenotype.
Introduction
Alzheimer's disease (AD) is a progressive, neurodegenerative condition that results in both cognitive and functional decline. Episodic memory loss has traditionally been considered the cardinal feature of the disease, as it is thought to be the first and most salient domain of cognition affected. Indeed, longstanding diagnostic criteria for AD emphasize the requirement for the presence of amnesia associated with at least one of several additional domains of impairment, including executive or visuospatial function, language, and praxis [1••] . However, heterogeneity in the clinical and pathoanatomic presentation of AD has become increasingly appreciated [2] [3] [4] [5] . Indeed, the recently updated clinical criteria for AD proposed by the National Institute on Aging-Alzheimer's Association workgroup incorporates nonamnestic presentations of the disease as potentially satisfying the core clinical features [6] . Three types of nonamnestic phenotypes in particular are considered by these criteria: (1) a language presentation, (2) a visuospatial presentation, and (3) executive dysfunction.
These "presentation" types correspond to three clinical syndromes that have been increasingly well defined and strongly associated with AD-related pathologic features. Although a variety of different names have been used to describe these syndromes, the following have become accepted terms in the literature and clinical practice: (1) logopenic primary progressive aphasia (LPA), (2) posterior cortical atrophy (PCA), and (3) frontal variant of AD (FvAD). A particular challenge diagnostically for these syndromes is their overlap with other non-AD dementias. For example, LPA shares features of progressive nonfluent aphasia (PNFA), a condition generally thought to be associated with tau-based frontotemporal dementia (FTD) [7, 8•] . Although relatively sophisticated cognitive testing may help differentiate these AD-associated conditions from non-AD dementias, it is unclear that these distinctions will be easy to apply outside specialty clinics. These patients underscore the value of in vivo molecular measures of AD, including cerebrospinal fluid markers of amyloid β (Aβ), and amyloid imaging.
This article will review these three syndromes, particularly focusing on data from studies that have applied amyloid imaging to these populations. In addition to providing support about the underlying cause, these data provide a perspective on the relationship between the distribution of amyloid plaques and the clinicoanatomic features of the syndromes, which has implications for disease pathophysiology. Imaging results will be compared with autopsy findings when available.
Amyloid Imaging
A definitive diagnosis of AD requires pathologic confirmation, and new criteria for this assessment were recently published [9] . Clinically, the underlying disease has generally been inferred on the basis of the cognitive and behavioral features of the presentation and has been supported by the presence of neuroimaging measures of neurodegeneration (e.g., hippocampal atrophy, posterior cingulate hypometabolism) commonly associated with AD. The emergence of biofluid and imaging methods to provide more direct measures of the molecular pathologic features in vivo has been one of the major achievements of the field over the last decade and has contributed significantly to our understanding of the disease process [10] and has inspired new targets for therapeutic intervention (e.g., preclinical AD) [11] .
Particularly compelling has been the emergence of amyloid imaging with positron emission tomography (PET), which allows visualization of fibrillar Aβ plaques. The first widely used ligand for this purpose was 11 C-labeled Pittsburgh compound B (PiB-C11) [12] . PET with PiB-C11 has consistently demonstrated the ability to discriminate between cognitively normal adults and patients with AD, predict progression in both preclinical and mild cognitive impairment populations, and correlate the findings with ex vivo histologic measurements of Aβ plaque burden [13] [14] [15] (for a review, see [16] ). Although the main limitation of PiB-C11 is the short half-life of carbon-11 (approximately 20 minutes) that prevents its widespread clinical use, several "second-generation" ligands that use the radiotracer fluorine-18 have been developed and display similar results in patient populations, including correlation with histologic findings obtained by biopsy or autopsy [17, 18•, 19] . Indeed, florbetapir F-18, or Amyvid, is the first amyloid imaging ligand to be approved for clinical use by the US Food and Drug Administration.
Logopenic Primary Progressive Aphasia
For the last several decades, two main forms of progressive aphasia have been described, which have carried the monikers of "semantic dementia" (SD) and "progressive nonfluent aphasia" (PNFA) [20, 21] . Both of these syndromes have traditionally been considered types of primary progressive aphasia (PPA) and are generally thought to be associated with FTD spectrum disease. Indeed, a number of studies have linked SD with ubiquitin-positive, TAR DNA-binding protein 43, a major subtype of FTD-related disease [7, [22] [23] [24] . Alternatively, PNFA is most commonly reported to be associated with non-AD, tau-positive disease [7, 22, 25•, 26] . Nonetheless, a number of clinicopathology series of PPA patients have reported relatively frequent cases with primarily AD. As more focused analysis of these cases were pursued, a relatively distinct language phenotype emerged, and this group has more recently been classified as having LPA [8, 27] .
LPA is characterized by prominent word-finding deficits, both in free speech and with naming. Although these patients can often speak with fluent utterances, there are frequent word-finding pauses. A hallmark feature is the presence of impaired repetition of speech, particularly for longer phrase lengths and sentences, reflecting the notion that a reduction in phonologic working memory is a major driver of the cognitive presentation. In distinction from SD and PNFA, respectively, these patients have intact single word comprehension and grammar. Structural and functional imaging with MRI and fluorodeoxyglucose (FDG) PET have demonstrated consistent involvement of posterior temporal and parietal perisylvian regions in the left hemisphere [27] [28] [29] . On the basis of still relatively limited autopsy data, with most prior to recent formally accepted diagnostic criteria [8• ], AD appears to be the most common underlying disease in these patients, but non-AD diseases have also been reported [7, 25•] . Nonetheless, LPA is often considered an atypical variant of AD.
There have now been several amyloid imaging studies of PPA, all with PiB PET [28, 30, 31•, 32••] . Consistent with the autopsy literature, these studies have reported that the vast majority of these patients have evidence of amyloid plaque deposition, marked by increased uptake of PiB-C11. Remarkably, the pattern of amyloid uptake in these cases was not clearly different from that in typical AD comparison groups. That is, despite the prominence of language symptoms and evidence of more focal left hemisphere neurodegenerative change, these patients did not display asymmetry in amyloid plaque distribution measured by PiB PET. For example, Leyton et al. [30] reported very similar levels of uptake in the left and right temporal and parietal lobes in LPA patients. Lehmann Although the finding of symmetric amyloid distribution in patients with evidence of much more focal left hemisphere involvement may be unexpected, autopsy data have provided similar findings. Mesulam et al. [7] performed both qualitative and quantitative analyses of both neuritic amyloid plaques and neurofibrillary tangles (NFTs) in PPA patients with AD [7] . They found no evidence of asymmetry in amyloid plaque burden, comparable to typical AD patients and consistent with the above-mentioned amyloid imaging data. However, they did report increased NFT burden in left hemisphere language regions, but this was not a universal finding among these patients. The finding that amyloid plaque burden does not strongly reflect the clinical phenotype is consistent with long-standing data demonstrating poorer correlation of amyloid plaque burden with cognitive severity relative to NFTs [33] . Nonetheless, the fact that the presence of NFTs also does not always demonstrate concordance with the focused language impairment in these patients adds to the mystery of the pathophysiologic process [7, 34, 35] . Importantly, autopsy studies have not revealed additional FTD spectrum disease in these cases and, thus, it is unlikely that the AD represents an incidental finding.
Finally, the fact that LPA is not always associated with AD whereas SD and PNFA may be in a minority of cases, as reported in both autopsy and amyloid imaging studies [28, 30, 36] , accentuates the potential role of amyloid imaging in these populations. Even detailed assessments of language and other cognitive function do not predict AD at an individual level in more than a probabilistic manner. Furthermore, these reports have come from dementia specialty clinics, and the granular language assessments applied may not be feasible in more general clinical practice.
Posterior Cortical Atrophy
The entity of PCA was first formally described by Cogan [37] and then expanded on by Benson et al. [38] approximately 25 years ago, but had not received much attention until the last decade. The syndrome is generally defined by a striking impairment of higher-order visual processing function out of proportion to other cognitive domains. Most cognitive deficits are attributable to occipitoparietal and occipitotemporal dysfunction, including impairment of visuospatial processing, elements of Bálint's and Gerstmann's syndromes, alexia, apraxia, and impairment of face/object visual recognition [39, 40•] . Although significant atrophy in the above-mentioned brain regions is frequently present on structural imaging, such "posterior atrophy" is not always observed in spite of the name. Functional imaging with FDG PET often reveals prominent hypometabolism in parietal and occipital cortex [32••, 41] . It is notable that there is significant overlap of the structural and functional cortical involvement in PCA with typical AD, making these conditions difficult to discriminate purely on the basis of neuroimaging [40•] .
Currently, there is not consensus on the diagnostic criteria for PCA, but proposed criteria emphasize the presence of visual processing deficits in the face of relatively preserved episodic memory and language function [42, 43] . Age of onset is also a diagnostic consideration, as these patients tend to present at a relatively young age, usually before 65 years, but this is by no means exclusionary. Perhaps related, in part, to the lack of definitive consensus criteria, PCA reflects a heterogeneous condition with regard to the underlying pathologic cause. Although there is some variability across the literature, most of these patients do appear to have AD-related disease [35, 36, 42, 44] . However, a variety of other conditions have also been associated with this syndrome, including corticobasal degeneration, dementia with Lewy bodies (DLB), and prion disease. It is not clear presently whether specific clinical features and structural or functional imaging aid in prediction of the underlying disease. Interestingly, in those with AD, NFT burden has been reported to be increased in primary visual cortex and visual association regions relative to other more typical structures affected by AD (e.g., hippocampus) [42, 45, 46] . However, whether or not the density of amyloid plaques is also greater in these regions has been inconsistent in the still limited autopsy literature, with some studies reporting increases and others a more typical distribution of senile plaques.
Given that there is pathoetiologic heterogeneity and the fact that prominent and relatively focal parietal dysfunction is not rare in AD (approximately 5-10 % in one series [3] ), molecular imaging has potentially significant utility in the diagnostic process. There are now several case reports and small series of patients with PCA who have undergone amyloid imaging (all with PiB PET). These studies have been consistent with the notion that most patients with this phenotype do have evidence of AD [31•, 47-50, 51•, 52] . However, it is worth noting that DLB, a condition marked by parkinsonism, visual hallucinations, and cognitive fluctuations, is also often associated with the presence of cortical amyloid plaques and positive amyloid imaging [53] , in addition to the synucleinrelated disease, and, thus, some proportion of these patients may have underlying DLB.
Several reports have indicated increased PiB uptake in occipital regions relative to that found in typical AD [31•, 48, 49, 52] . For example, in "PiB-positive" PCA patients (n =3), Wolk et al. [31• ] described a lower ratio of anterior-to-posterior PiB uptake relative to that in typical AD, with the opposite pattern for FDG PET, the latter consistent with the lower posterior metabolism in PCA. Lehmann et al. also reported some evidence of increased visual association cortex PiB uptake in PCA and a somewhat more constrained distribution within the visual network. However, as with the pathology data, evidence of greater visual system amyloid plaque burden has not been a universal finding as assessed with amyloid imaging [47, 51•] .
Frontal Variant of AD
Although somewhat less studied and less clearly defined than LPA and PCA, it is apparent that AD can sometimes present with a more prominent dysexecutive or behavioral phenotype [54] [55] [56] [57] . Furthermore, a number of groups have reported some proportion of clinical FTD patients with primary AD on autopsy [36, 58] . In particular, FvAD has been associated with early onset cases of AD (less than 65 years old), in which a subset of patients display structural and/or metabolic evidence of a predilection for neurodegeneration in frontal-control networks [2, 32••, 59] .
The most comprehensive pathology-related description of FvAD is the report of three patients by Johnson et al. [57] . They selected these patients from a series of 63 pathologically proven AD cases based on disproportionate impairment on psychometric measures that measure executive function. They reported a tenfold increase in the density of NFTs in frontal cortical regions disproportionate with other structures. In contrast, they did not find differences in amyloid plaque burden. This group has also described a dysexecutive subtype of mild cognitive impairment and has reported greater frontal AD pathologic features in one of these patients who was autopsied at this disease stage, suggesting that FvAD can be differentiated from typical AD in predementia stages [60, 61] .
There have not been systematic studies with amyloid imaging of individuals with suspected FvAD. However, studies of clinically diagnosed FTD patients have revealed some proportion that demonstrate positive amyloid scans, including those with primarily executive or behavior symptoms (as opposed to SD or PNFA) [62] . These individuals are likely best classified as having FvAD. In a study in which patients were classified as having "possible AD" (n =7) because of atypical presentations with more prominent nonmemory cognitive or behavioral symptoms, or were classified as having "dementia of uncertain etiology (DUE)" (n =10), with many having significant executive/ behavioral symptoms contributing to their diagnostic confusion, seven had positive amyloid scans. In particular, DUE patients tended to have greater hypometabolism of anterior regions as revealed by FDG PET, consistent with their phenotype and suggestive of FvAD. Nonetheless, with the exception of one patient, there was no evidence of greater amyloid uptake in anterior brain regions (frontal cortex, anterior cingulate) in these cases. Finally, studies of early onset AD with associated FDG PET frontal-control network neurodegeneration do not display evidence of more significant amyloid deposition in these regions on the basis of PiB PET. Thus, the amyloid imaging data parallel the findings of Johnson et al. [57] , who found an increase in the density of NFTs, but not amyloid plaques, in the frontal cortex of these patients.
Conclusions
The atypical presentations described herein underscore the potential utility of biomarkers that are specific for the molecular pathologic features of AD, such as amyloid imaging. Although LPA, PCA, and FvAD are somewhat circumscribed syndromes, their clinical presentation is still associated with differing degrees of uncertainty with regard to the underlying pathologic cause. Further, diagnostic criteria are still limited and in evolution, with the diagnostic criteria for LPA being the most developed and those for FvAD being the least developed, and the relative sensitivity and specificity of these designations remain largely unknown. As noted earlier, application of these criteria may be more challenging outside dementia specialty clinics. Thus, in addition to enhancing our understanding of these conditions, amyloid imaging is likely to provide critical information with regard to the cause in these cases in the clinical setting. Of course, the value of diagnostic accuracy will be greatly enhanced by the development of more disease specific interventions.
It is also worth noting that these three syndromes represent probable ends of the spectrum with regard to the heterogeneity of AD and that there are certainly patients who would be classified as "atypical," but defy an obvious syndromic category, and who may ultimately have underlying AD as the primary driver of their cognitive impairment. As an example, the case series described earlier by Wolk et al. [31• ] included 17 patients who were given a designation of either possible AD due to atypical features or DUE for which no consensus could be reached by an experienced team of clinicians at an AD research center. Of these 17 patients, seven (41 %) were considered "positive" for cerebral amyloid as measured by PiB PET, suggesting that this is a mixed group in which amyloid imaging can provide increased diagnostic certainty. Further, a number of clinicopathology series have suggested that phenotypes which are traditionally thought to be associated with non-AD dementia have a significant minority of cases associated with AD histopathologic features [36, 58] . Although the actual proportion of AD patients who have an atypical course or presentation is difficult to determine, some studies have suggested anywhere from 10 to 25 % of patients will not follow the classic AD pattern of cognitive deficits [3, 63] . Although biomarkers of neurodegeneration, such as FDG PET and structural MRI, may offer additional insight into the likely cause, they tend to recapitulate the pattern of the clinical phenotype rather than resolve the molecular pathologic features. In these instances, amyloid imaging is likely most valuable, as also suggested by recent "Appropriate use criteria for amyloid PET" proposed by the Amyloid Imaging Task Force, the Society for Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association [64••], criteria developed in the context of Food and Drug Administration approval for Amyvid.
In addition to the potential clinical role of amyloid imaging in these atypical phenotypes, it also offers some insight into the pathobiology of AD. Particularly striking is the generally "normal" appearance of the distribution of amyloid plaques despite the sometimes very focal nature of these presentations. Although the notion that amyloid plaques, as opposed to NFTs, do not correlate well with cognition is not a new one [33] , these cases offer extreme examples. In light of the generally accepted antecedent nature of amyloidogenesis, the question remains why NFTs and neurodegenerative change occur more selectively in these focal cases despite a typical amyloid plaque distribution. Recent work has suggested that although default mode network involvement is common to both typical and atypical cases, different networks display additional more focal involvement in, for example, LPA (left language network) versus PCA (higher visual network) [32••, 59] . What drives this differential selectivity may help reveal the keys to the progression of not only these atypical cases, but also AD more generally.
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